A short report on the tumor suppressor role of BIRC7 in pancreatic cancer
DOI:
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20212839Keywords:
BIRC7, Tumor suppressor, Pancreatic cancer, PADC, Gene mutationAbstract
Pancreatic cancer (PC) is accepted to be an aggressive malignancy among all type of cancers due to its poor prognosis and high cancer-led mortality ratio mostly affecting male community in older age. Multiple genes are involved in PC initiation, progression and metastasis including K-RAS, CDKN2A, p53, SMAD4. Baculoviral IAP repeat containing 7 (BIRC7) commonly known as Livin, an inhibitor of apoptosis protein (IAP) involved in the inhibition of cell death via apoptosis by preventing caspase activity through various approaches. The biological role of BIRC7 was previously identified in multiple cancers but ill investigated in PC. In this study, we investigate the function role of BIRC7 in PC. Multiple phenotypic tests including wound healing assay, CCK8 assay, trans-well assay and colony formation assay was run to rule out BIRC7 gene effect on PC genesis. We for the first time indicated that, overexpression of BIRC7 significantly reduced the proliferation, development, progression and metastasis of PANC-1 cell in vitro. Therefore, we anticipated that BIRC7 gene is a suppressor gene and might be a suitable candidate gene for therapeutic purposes in PC.
Metrics
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.
Cancer WS. Facts and Figures 2019. American Cancer Society: Atlanta, GA, USA. 2019.
Rahib L. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913-21.
Khan AA. An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression. Cancer Metastasis Rev. 2021;40(1):245-72.
Owens TW. Inhibitor of Apoptosis Proteins: Promising Targets for Cancer Therapy. J Carcinog Mutagen. 2013;14.
Plati J, Bucur O, Khosravi-Far R. Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb). 2011;3(4):279-96.
Budhidarmo R, Day CL, IAPs: Modular regulators of cell signalling. Semin Cell Dev Biol. 2015;39:80-90.
Lopez J, Meier P. To fight or dieinhibitor of apoptosis proteins at the crossroad of innate immunity and death. Current Opinion in Cell Biol. 2010;22(6):872-81.
Nachmias B. Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Cancer Res. 2003;63(19):6340-9.
Rigato DB, Mateus Reis Silva CS, Machado-Neto JA, Costa-Lotufo LV, Jimenez PC. BIRC7 (baculoviral IAP repeat containing 7). Atlas Genetics Cytogenetics Oncol Haematol. 2020.
Liu KP. BIRC7 promotes epithelial-mesenchymal transition and metastasis in papillary thyroid carcinoma through restraining autophagy. Am J Cancer Res. 2020;10(1):78-94.
Li F. Livin promotes progression of breast cancer through induction of epithelial-mesenchymal transition and activation of MKT signaling. Cellular Signalling. 2013;25(6):1413-22.
Dasgupta A. Expression and functional role of inhibitor-of-apoptosis protein livin (BIRC7) in neuroblastoma. Biochem Biophys Res Commun. 2010;400(1):53-9.
Yu L, Wang Z. Effects of Livin gene RNA interference on apoptosis of cervical cancer HeLa cells and enhanced sensitivity to cisplatin. J Huazhong Univ Sci Technolog Med Sci. 2009;29(5):625-30.
Xi RC, Biao WS, Gang ZZ. Significant elevation of survivin and livin expression in human colorectal cancer: inverse correlation between expression and overall survival. Onkologie. 2011;34(8-9):428-32.
Wang S. miR-216a-mediated upregulation of TSPAN1 contributes to pancreatic cancer progression via transcriptional regulation of ITGA2. Am J Cancer Res. 2020;10(4):1115-29.
Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem. 2001;276(5):3238-46.
Gazzaniga P, Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol. 2003;14(1)85-90.
